On Nov 8, 2024, Roche Diagnostics enhanced the company's long term commitment to China's local healthcare industry, to ...

Barclays analyst Emily Field maintained a Hold rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of ...

Data from two Alzheimer’s tests being developed by Roche Holding AG showed high accuracy in detecting the disease in patients being tested for the condition. The tests measure biomarkers in the blood ...

The global AI in pathology market is projected to reach USD 169.8 million by 2029 from USD 82.8 million in 2024, at a high ...

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

A major EU project coordinated from UCD is set to push the frontiers of biomedical research by exploring the transformative potential of extracellular vesicles (EVs).

The global antimicrobial susceptibility testing market is projected to reach USD 5.68 billion by 2029 from USD 4.45 billion in 2024, growing at a CAGR of 5.0% % during the forecast period. Major ...